Abstract:Background: Mild cognitive impairment (MCI) is an important stage between the normal cognitive decline of aging and dementia. The aim of this study was to compare and harmonize the recommendations for the diagnosis and treatment of MCI based on current clinical practice guidelines. Methods: We searched the PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, and Chinese Biological Medicine Database from their inception date to April 24, 2021 to identify all published guidelines on MCI. The qualities of the eligible guidelines were appraised by two reviewers using the Appraisal of Guidelines for Research and Evaluation II instrument. Results: Thirteen guidance documents (four guidelines and nine consensus statements) with specific recommendations were included. Nine guidelines and consensus statements covered the screening and diagnosis of MCI. The evaluation of the documents showed that neuropsychological testing and biomarker assessments were the most common recommendations for the diagnosis of MCI. Nine of the 13 guidance documents covered the treatment and management of MCI. The recommendations for the treatment and management were classified into four categories, namely: intervention for risk reduction, pharmacologic interventions, non-pharmacologic interventions, and counseling. Regarding pharmacological interventions, three guidelines recommend no pharmacologic intervention. The use of cholinesterase inhibitors for MCI is contraindicated in three guidance documents, whereas one proposes that cholinesterase inhibitors and memantine should be deprescribed. EHb761 ® , Chinese herbal decoctions, and Chinese traditional patent medicine are recommended in two documents. A total of seven guidance documents recommend non-pharmacological interventions, including physical activity interventions, cognitive interventions, dietary and nutritional interventions, and acupuncture. Conclusion: An updated search for possible evidence on the diagnosis and treatment of MCI is needed. Potentially effective diagnoses and treatments, either conventional or complementary, and alternative therapies should be highly valued and addressed in correlation with the supporting evidence.

Chinese guidelines on management of hepatic encephalopathy in cirrhosis

[Chinese guidelines on the management of hepatic encephalopathy in cirrhosis (2024)]

Chinese Guidelines On The Management Of Liver Cirrhosis (Abbreviated Version)

Multivariate analysis of hepatic encephalopathy occurrence in patients with liver failure

Chinese guidelines on the management of ascites and its related complications in cirrhosis

Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association

Chinese consensus on the management of liver cirrhosis

The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas

Systems of care that improve outcomes for people with hepatic encephalopathy

Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments

Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)

Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension.

Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma

Critical Appraisal of Chinese 2017 Guideline on the Management of Hepatocellular Carcinoma.

Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases

Diagnosis and Treatment for Mild Cognitive Impairment: A Systematic Review of Clinical Practice Guidelines and Consensus Statements

The assessment and management of cirrhotic patients with encephalopathy

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

The Role of Intestinal Bacteria and Gut–Brain Axis in Hepatic Encephalopathy

Detection of minimal hepatic encephalopathy in patients with cirrhosis based on the Stroop-CN model (NCRCID-CHESS 2106): a prospective multicenter study

Chinese Consensus on Clinical Diagnosis and Therapy of Liver Cirrhosis